| First Author | de Souza CO | Year | 2022 |
| Journal | J Clin Invest | Volume | 132 |
| Issue | 21 | PubMed ID | 36066975 |
| Mgi Jnum | J:331374 | Mgi Id | MGI:7388085 |
| Doi | 10.1172/JCI160097 | Citation | de Souza CO, et al. (2022) GPR92 activation in islet macrophages controls beta cell function in a diet-induced obesity model. J Clin Invest 132(21) |
| abstractText | The molecular mechanisms underlying obesity-induced increases in beta cell mass and the resulting beta cell dysfunction need to be elucidated further. Our study revealed that GPR92, expressed in islet macrophages, is modulated by dietary interventions in metabolic tissues. Therefore, we aimed to define the role of GPR92 in islet inflammation by using a high-fat diet-induced (HFD-induced) obese mouse model. GPR92-KO mice exhibited glucose intolerance and reduced insulin levels - despite the enlarged pancreatic islets - as well as increased islet macrophage content and inflammation level compared with WT mice. These results indicate that the lack of GPR92 in islet macrophages can cause beta cell dysfunction, leading to disrupted glucose homeostasis. Alternatively, stimulation with the GPR92 agonist farnesyl pyrophosphate results in the inhibition of HFD-induced islet inflammation and increased insulin secretion in WT mice, but not in GPR92-KO mice. Thus, our study suggests that GPR92 can be a potential target to alleviate beta cell dysfunction via the inhibition of islet inflammation associated with the progression of diabetes. |
